1. OC-0277 Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC. (April 2019) Authors: Siva, S.; Bressel, M.; Sandhu, S.; Tran, B.; Mooi, J.; Lewin, J.; Loi, S.; Toner, G.; Moon, D.; Goad, J.; Shaw, M.; Chander, S.; Eade, T.; Guminski, A.; Jayamanne, D.; Pryor, D.; Cuff, K.; Wood, S.; Lawrentschuk, N.; Murphy, D. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗